According to Pluo Pharmaceutical's announcement, the company's share repurchase is used to cancel and reduce registered capital. The maximum repurchase price is not more than 20 yuan/share, and the total repurchase capital is not less than 100 million yuan and not more than 150 million yuan. The repurchase period is within 6 months from the date the shareholders' meeting reviews and approves the plan. As of August 31, 2026, the company had repurchased a total of 5.4101 million shares through centralized bidding transactions, accounting for 0.47% of the total share capital. The highest transaction price was 19.98 yuan/share, the lowest transaction price was 17.05 yuan/share, and the total transaction amount was 99.9897 million yuan.

According to Pluo Pharmaceutical's announcement, the company's share repurchase is used to cancel and reduce registered capital. The maximum repurchase price is not more than 20 yuan/share, and the total repurchase capital is not less than 100 million yuan and not more than 150 million yuan. The repurchase period is within 6 months from the date the shareholders' meeting reviews and approves the plan. As of August 31, 2026, the company had repurchased a total of 5.4101 million shares through centralized bidding transactions, accounting for 0.47% of the total share capital. The highest transaction price was 19.98 yuan/share, the lowest transaction price was 17.05 yuan/share, and the total transaction amount was 99.9897 million yuan.